Germany says vaccine rollout on track despite CureVac trial flop

A failure of German biotech CureVac to meet its efficacy goal in a late-stage trial for its COVID-19 vaccine will not impact the speed of Germany's vaccination rollout, the health ministry said on Thursday. "The announcement does not have an impact on the speed of our vaccination rollout," a health ministry spokesperson said, declining to comment on the study results.

CureVac said on Wednesday its COVID-19 vaccine was only 47% effective in a late-stage trial, missing the study's main goal and throwing in doubt the potential delivery of hundreds of millions of doses to the European Union.

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)